The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery
Open accessAbstract
Advancements in biotechnology and protein engineering expand the availability of various therapeutic proteins including vaccines, antibodies, hormones, and growth factors. In addition, protein drugs hold many therapeutic advantages over small synthetic drugs in terms of high specificity and activity. This has led to further R&D investment in protein-based drug products and an increased number of drug approvals for therapeutic proteins. However, there are many biological and biopharmaceutical obstacles inherent to protein drugs including physicochemical and enzymatic destabilization, which limit their development and clinical application. Therefore, effective formulations of therapeutic proteins are needed to overcome the various physicochemical and biological barriers. In current medical practice, protein drugs are predominantly available in injectable formulations, which have disadvantages including pain, the possibility of infection, high cost, and low patient compliance. Consequently, non-invasive drug delivery systems for therapeutic proteins have gained great attention in the research and development of biomedicines. Therefore, this review covers the various formulation approaches to optimizing the delivery properties of protein drugs with an emphasis on improving bioavailability and patient compliance. It provides a comprehensive update on recent advancements in nanotechnologies with regard to non-invasive protein drug delivery systems, which is also categorized by the route of administrations including oral, nasal, transdermal, pulmonary, ocular, and rectal delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Approaches for enhancing oral bioavailability of peptides and proteins
Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H. S., & Mitra, A. K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.030 · Cited by 681 · cited 1×
“Particularly, the strongly acidic gastric environment (pH 1 – 3) causes destabilization of protein drugs in the stomach, but chemical degradation reduces significantly in the ileum and colon due to higher pHs [12,16,19].”
BackgroundDelivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Mandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481
Hydrogels for oral delivery of therapeutic proteins
Peppas, N. A., Wood, K. M., & Blanchette, J. O. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.881 · Cited by 161
Davoudi, Z., Peroutka‐Bigus, N., Bellaire, B., Wannemuehler, M., Barrett, T. A., Narasimhan, B., & Wang, Q. (2018) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36305 · Cited by 118
Makhlof, A., Fujimoto, S., Tozuka, Y., & Takeuchi, H. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.12.008 · Cited by 90
Oh, E. J., Choi, J.-S., Kim, H., Joo, C.-K., & Hahn, S. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.003 · Cited by 77
Zheng, H., Yin, L., Zhang, X., Zhang, H., Hu, R., Yin, Y., Qiu, T., Xiong, X., & Wang, Q. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2279 · Cited by 64
Cited by
Chitosan Derivatives and Their Application in Biomedicine
Wang, W., Meng, Q., Li, Q., Liu, J., Zhou, M., Jin, Z., & Zhao, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020487 · Cited by 982
Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102487 · Cited by 487
Metadata
- Authors
- Bajracharya, R., Song, J. G., Back, S. Y., & Han, H.-K.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2019
- Volume
- 17
- Pages
- 1290-1308
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2972610603
- Cited by
- 182
- References
- 8
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.